[18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma

Launched by WESTERN UNIVERSITY · May 20, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called PSMA PET/CT to help find hidden spots of metastatic clear cell kidney cancer. Traditional imaging methods like CT scans or MRIs are commonly used to check for kidney cancer, but they may not always detect all areas where the cancer has spread. The goal of this study is to see if PSMA-targeted PET imaging, which can better identify these hidden areas, can improve how doctors manage the disease, especially in patients with widespread cancer.

To participate in this trial, you need to be an adult (18 years or older) with confirmed metastatic clear cell renal cell carcinoma. You should also have had a recent CT or MRI scan of your chest, abdomen, and pelvis, unless there are medical reasons preventing this. Unfortunately, pregnant or breastfeeding individuals, or those with certain health issues, cannot join the study. If you participate, you'll undergo a PSMA PET scan, which involves lying flat for about 30 minutes while images are taken. This could help your healthcare team better understand your cancer and plan the best treatment for you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Men and women with histologically-proven, metastatic renal cell carcinoma (RCC)(TNM stage Tany, Nany, M1)
• • 2. Must have baseline conventional imaging of the chest, abdomen, and pelvis with contrast-enhanced CT or MRI within 5 weeks of enrolment. Contrast is required unless the participant cannot for medical reasons (ie renal failure).
• • Exception: Unenhanced CT of the chest is acceptable Exception: Unenhanced MRI of abdomen and pelvis is acceptable in cases of renal failure
• Exclusion Criteria:
• • 1. Pregnant or breastfeeding
• • 2. Age less than 18
• • 3. Histology does not have any clear cell component
• • 4. Unable to lie flat for 30 minutes for the scan
• • 5. History of prior malignancy (except non-melanoma skin cancer)
• • 6. Unable to provide informed consent
• • 7. Inadequate liver function
• • 8. Systemic or radiation-based cancer treatment is needed urgently and anticipated to begin before PSMA scan can take place
• • 9. Previously exposed to systemic or radiation cancer therapy (except radiation for skin cancer)